Key result
Cardiac resynchronization therapy was cost-effective compared with medical therapy alone in Greece, with an incremental cost of €6,045 per QALY gained (95% CI €4,292-9,411).
Why the study?
Does cardiac resynchronization therapy plus medical therapy improve cost-effectiveness (cost per QALY) compared to medical therapy alone in patients with moderate-to-severe heart failure in Greece?
Population
813 patients with moderate-to-severe heart failure with markers of cardiac dyssynchrony
Comparison
Cardiac resynchronization therapy plus optimal… vs Optimal pharmacological treatment alone
Design
Other, randomized clinical trial (underlying CARE-HF trial)
Follow-up
lifetime perspective
Authors
Loading...
Supports CRT cost-effectiveness in Greece; leaves open generalizability to other systems.
RCT (n=813)
randomized
Does cardiac resynchronization therapy plus medical therapy improve cost-effectiveness (cost per QALY) compared to medical therapy alone in patients with moderate-to-severe heart failure in Greece?
Cardiac resynchronization therapy is a highly cost-effective treatment compared with traditional pharmacological therapy in the Greek healthcare setting for patients with moderate-to-severe heart failure and dyssynchrony.
Maniadakis et al. (2011) conducted an RCT in moderate-to-severe heart failure with markers of cardiac dyssynchrony (n=813). Cardiac resynchronization therapy (CRT) plus medical therapy vs. Optimal pharmacological treatment alone was evaluated on Cost per quality-adjusted life year (QALY) gained (95% CI 4,292-9,411). Cardiac resynchronization therapy was cost-effective compared with medical therapy alone in Greece, with an incremental cost of €6,045 per QALY gained (95% CI €4,292-9,411).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: